Guangxi Chisage Fine Chemical Technology Co., Ltd. Class A

Guangxi Chisage Fine Chemical Technology Co., Ltd. Class A

SSZSE:000953
5.20
CNY
-0.13
(-2.44%)
0.01EPS
757.88P/E
2.56BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
2.7
1.89
2.12
1.35
0.75
0.79
0.48
0.71
0.49
0.43
0.49
0.59
0.55
0.46
Basic EPS, GAAP
0.1
0.06
-0.36
-0.48
0.1
-0.93
-0.21
0.09
0.03
-0.27
-0.03
0.22
0.02
0.01
Free Cash Flow per Basic Share
-0.41
-0.88
-0.37
0.27
-1.17
-0.18
-0.04
0.14
- -
-0.09
0.02
-0.12
0.14
- -
Dividend per Share
0.24
0.24
0.16
0.13
0.04
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
1.84
0.81
0.37
-0.3
0.08
-0.85
0.08
0.46
0.48
0.21
0.18
0.4
0.42
0.42
Tangible Book Value per Share
1.84
0.81
0.37
-0.3
0.08
-0.85
-0.34
0.13
0.16
0.14
0.12
0.34
0.36
0.37
Basic Weighted Avg Shares
294
294
294
294
294
294
290
344
334
372
385
360
326
366
Sales/Revenue/Turnover
792
555
623
398
221
231
139
244
162
161
187
212
180
168
Operating Margin (%)
-14.34
-41.77
-5.85
-35.53
-7.18
-44.51
-26.41
20.06
10.86
-7.51
-4.37
4.33
5.39
3.51
Depreciation Expense
76
63
51
51
49
48
31
12
13
13
15
17
18
- -
Net Income, GAAP
30
18
-107
-142
29
-274
-61
31
10
-100
-12
79
7
3
Effective Tax Rate (%)
- -
- -
- -
- -
4.27
- -
- -
16.82
17.88
- -
- -
12.52
- -
8.91
Profit Margin (%)
3.78
3.21
-17.18
-35.59
13.34
-118.47
-43.93
12.71
6.17
-62.53
-6.17
37.47
3.63
2.01
Working Capital
-544
-432
-542
-649
-496
-581
-198
-41
-35
-64
-79
3
22
28
LT Debt
55
36
16
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
542
240
108
-89
23
-250
36
182
194
94
83
162
171
172
Return on Invested Capital (%)
2.13
2.64
- -
- -
-66.7
- -
- -
28.66
5.53
- -
- -
67.06
- -
2.4
Return on Capital (%)
7.97
10.21
- -
- -
88.42
- -
- -
27.93
6.12
- -
- -
64.9
- -
1.98
Return on Common Equity (%)
4.89
4.57
-61.53
- -
- -
- -
- -
32.5
5.82
-78.69
-16.01
74.89
4.38
2.26

Capital Structure

CNY

•

in mil. unless spec.
Jun'25
Dec'25
Mar'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
366
366
366
Market Capitalization
2,534
2,643
2,563

Working Capital

CNY

•

in mil. unless spec.
Jun'25
Dec'25
Mar'26
Total Current Assets
125
109
120
Cash, Cash Equivalents & STI
59
56
59
Accounts Receivable, Net
8
23
14
Inventories
44
28
35
Total Current Liabilities
108
87
92
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-114.26%
8.72%
5.49%
Free Cash Flow
-528.91%
-777.1%
-200.04%
Net Income, GAAP
-348.22%
-427.21%
-91.77%
Sales/Revenue/Turnover
-6.02%
-3.98%
-15.05%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
62
66
38
45
212
2025
41
40
- -
50
180
2026
37
- -
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.01
0.21
- -
0.22
2025
- -
0.01
- -
- -
0.02
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Jian Guo He
Full Time Employees
170
Sector
Process industries
Industry
Chemicals: agricultural
Address
No. 40, Liujia Town Hechi GG China 547007
IPO Date
Dec 2, 1999
Business
Guangxi Hechi Chemical Co., Ltd. is engaged in the production and distribution of a variety of chemical goods and pharmaceutical intermediates across China. The company's product line includes conventional agricultural essentials such as urea and composite fertilizers, alongside industrial chemicals like liquid carbon dioxide, methanol, ammonia, and sulfur. Strategically, the enterprise has intensified its focus on the research, production, and sale of pharmaceutical intermediates, which encompass components for antimalarial medications, progestins, and nutritional supplements. Originally founded in 1969 as the Guangxi Hechi Nitrogen Fertilizer Plant, the firm executed a pivotal business transition around 2019, reorienting its primary operations toward bio-pharmaceuticals and specialized fine chemical segments through targeted acquisitions. The company, headquartered in Hechi, China, caters to both domestic and global markets, with its products reaching countries like India, Finland, and regions such as Taiwan.